PERFORMA: Pemvidutide Phase 3 trial (NCT07795164)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Recruiting
- Enrolment
- 1,800
- estimated
- Start
- 30 Jul 2026 (actual)
- Primary completion
- Dec 2028 (estimated)
- Sponsor
- Altimmune, Inc.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Pemvidutide 1.8 mg | Experimental | Drug: Pemvidutide | Not stated |
| Pemvidutide 2.4 mg | Experimental | Drug: Pemvidutide | Not stated |
| Placebo | Placebo comparator | Other: Placebo | Not stated |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Clinical Outcome Event | Baseline through end of study (approximately Month 60) |
| Histological Response: MASH resolution | Baseline through Week 52 |
| Histological Response: Fibrosis improvement | Baseline through Week 52 |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH | Baseline through Week 52 |
| HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis | Baseline through Week 52 |
| Anthropometric parameters: Relative (%) change from baseline in body weight (kg) | Baseline through End of Study (approximately Month 60) |
| Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2) | Baseline through End of Study (approximately Month 60) |
| Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm) | Baseline through End of Study (approximately Month 60) |
| Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L) | Baseline through End of Study (approximately Month 60) |
| Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score | Baseline through End of Study (approximately Month 60) |
| Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan | Baseline through End of Study (approximately Month 60) |
| HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire. | Baseline through End of Study (approximately Month 60) |
| HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores. | Baseline through End of Study (approximately Month 60) |
| HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores. | Baseline through End of Study (approximately Month 60) |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.